MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Sarepta Therapeutics Company Profile (NASDAQ:SRPT)

Consensus Ratings for Sarepta Therapeutics (NASDAQ:SRPT) (?)
Ratings Breakdown: 5 Sell Rating(s), 6 Hold Rating(s), 7 Buy Rating(s)
Consensus Rating:Hold (Score: 2.11)
Consensus Price Target: $24.35 (30.51% upside)

Analysts' Ratings History for Sarepta Therapeutics (NASDAQ:SRPT)
Show:
DateFirmActionRatingPrice TargetActions
6/27/2016Robert W. BairdReiterated RatingOutperform$23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/27/2016William BlairReiterated RatingMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/25/2016Jefferies GroupReiterated RatingUnderperform$7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/22/2016WedbushReiterated RatingOutperform$36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/21/2016OppenheimerReiterated RatingOutperform$60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2016Piper JaffrayUpgradeUnderweight -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016WBB SecuritiesReiterated RatingBuy$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Janney Montgomery ScottReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Cowen and CompanyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/3/2016RBC CapitalReiterated RatingHold$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/3/2016Leerink SwannReiterated RatingUnderperform$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/3/2016JMP SecuritiesReiterated RatingSell$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/27/2016SunTrustReiterated RatingReduceView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2016Ladenburg ThalmannDowngradeMarket Perform -> Underperform$13.00 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/24/2016Needham & Company LLCReiterated RatingBuy$53.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/8/2015Roth CapitalReiterated RatingBuy$50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/23/2015Bank of AmericaInitiated CoverageBuy$49.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/1/2015SusquehannaBoost Price TargetNeutral$33.00 -> $36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/23/2015Deutsche BankReiterated RatingHold$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2015Canaccord GenuityUpgradeHold -> Buy$16.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2015Northland SecuritiesUpgradeMarket Perform -> Outperform$3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/27/2014Stifel NicolausDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/7/2014Credit SuisseReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Sarepta Therapeutics (NASDAQ:SRPT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/5/2016Q1($1.30)($1.15)$0.18 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2016Q4($1.18)($1.30)$1.25 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($1.19)($1.25)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($1.21)($1.01)$0.31 million$0.01 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($1.00)($1.49)$0.78 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2015Q414($0.82)($0.94)$1.56 million$0.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314($0.96)($0.70)$3.07 million$1.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.76)($0.85)$4.30 million$2.58 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.80)($0.75)$3.45 million$6.09 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q413($0.69)($0.77)$4.53 million$2.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q313($0.65)($0.63)$4.57 million$4.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q2 2013($0.67)($0.46)$5.08 million$3.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2013Q1 2013($0.62)($0.41)$5.85 million$4.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/7/2013Q4 2012($0.26)($2.36)$6.71 million$7.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2012($0.27)($2.17)$10.06 million$7.57 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Sarepta Therapeutics (NASDAQ:SRPT)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($1.40)($1.17)($1.29)
Q2 20165($1.32)($0.62)($1.08)
Q3 20166($1.19)($0.59)($0.93)
Q4 20166($1.00)($0.47)($0.76)
Q1 20171($0.68)($0.68)($0.68)
Q2 20171($0.60)($0.60)($0.60)
Q3 20171($0.49)($0.49)($0.49)
Q4 20171($0.39)($0.39)($0.39)
(Data provided by Zacks Investment Research)
Dividend History for Sarepta Therapeutics (NASDAQ:SRPT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Sarepta Therapeutics (NASDAQ:SRPT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/16/2016M Kathleen BehrensDirectorBuy10,000$14.54$145,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2016M Kathleen BehrensDirectorBuy65,000$16.54$1,075,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/14/2013Anthony ChaseDirectorBuy10,000$13.95$139,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013M Kathleen BehrensDirectorBuy6,500$37.04$240,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013John HodgmanDirectorSell5,556$34.97$194,293.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/22/2013Anthony ChaseDirectorBuy3,500$32.68$114,380.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2013Sandesh MahatmeCFOBuy5,000$31.10$155,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/14/2013Anthony R ChaseDirectorBuy10,000$38.50$385,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/7/2012M Kathleen BehrensDirectorBuy17,500$14.73$257,775.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Sarepta Therapeutics (NASDAQ:SRPT)
DateHeadline
06/29/16 06:29 PMSarepta Therapeutics, Inc. (NASDAQ:SRPT) Earnings Review and Target Focus - Telanagana Press
06/28/16 06:26 PMCovering the Bases on Sarepta Therapeutics, Inc. (NASDAQ:SRPT): Where is the Stock Going? - Press Telegraph
06/28/16 06:26 PMSarepta Therapeutics, Inc. (NASDAQ:SRPT): Reviewing Stock Performance - Press Telegraph
06/28/16 03:32 PMSAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/28/16 08:39 AMSarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : June 28, 2016 -
06/27/16 06:26 PMDrug Trial Extension By FDA Doesn't Change Baird's Outlook On Sarepta
06/27/16 03:35 PM​Why Sarepta just made its soon-to-begin drug trial even longer -
06/27/16 01:35 PMStill Little Hope Of FDA Approval For Sarepta, SunTrust Says Sell -
06/26/16 10:39 AMWilliam Blair Weighs In on Sarepta Therapeutics Inc (SRPT) Following Changes In ESSENCE Trial - Smarter Analyst
06/26/16 09:12 AM3 Tempting Stocks to Avoid -
06/23/16 02:50 PMSarepta Therapeutics: Radio Silence -
06/23/16 02:07 PMSarepta Push for Duchenne Drug Approval Helped by Clinical Trial Changes -
06/22/16 10:34 AMSarepta Therapeutics (NASDAQ:SRPT) Analyst Rating Consensus - Trade Calls
06/21/16 10:31 AMOppenheimer Pounds the Table on Sarepta Therapeutics Inc (SRPT) - Smarter Analyst
06/20/16 08:02 AMSarepta Therapeutics, Inc. (NASDAQ:SRPT) Analyst Price Targets For The Coming Week - Fiscal Standard
06/18/16 10:36 AMSarepta Therapeutics Inc. (SRPT) Drops 7.9% on June 16 - Equities.com
06/17/16 07:15 AMSarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : June 17, 2016 -
06/16/16 06:46 PMRatings Analysis of: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - News Oracle
06/16/16 06:46 PMThis Hot Stock is Trending: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - News Oracle
06/15/16 06:27 PMAnalyst Earnings Report: UBS Group AG (NYSE:UBS), Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Beacon Chronicle
06/14/16 06:13 PMAnalyst's Valuable Buzzers: Valeant Pharmaceuticals (NYSE:VRX) , Sarepta Therapeutics, (NASDAQ:SRPT) - Street Updates
06/14/16 06:13 PMAnalyst Overview: Huntsman Corporation (NYSE:HUN), Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Beacon Chronicle
06/14/16 08:47 AMSarepta seen holding onto recent gains -
06/13/16 06:06 PMAnalyst Recommendations on These Hot Stocks: Canadian Solar Inc. (NASDAQ:CSIQ), Sarepta Therapeutics, Inc ... - Beacon Chronicle
06/13/16 09:33 AMHC Stocks Movements: Brookdale Senior Living, Inc. (NYSE:BKD), Sarepta Therapeutics Inc (NASDAQ:SRPT) - share market updates (press release)
06/11/16 09:31 AMPrice Target Highlight: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - News Oracle
06/10/16 06:55 PMBiotech Updates: Analysts Offer Commentary on Gilead Sciences, Inc. (GILD) and Sarepta Therapeutics Inc (SRPT) - Smarter Analyst
06/10/16 03:34 PMSAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial St -
06/10/16 12:26 PMSarepta Therapeutics: And Now We Wait -
06/10/16 09:36 AMBiogen Inc (NASDAQ:BIIB) & Sarepta Therapeutics (NASDAQ:SRPT) are Hot Stocks - Wall Street 24
06/10/16 09:36 AMEarnings Expectations of the Stocks: Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Regions Financial Corporation ... - Beacon Chronicle
06/09/16 07:04 PMAnalyst Earnings Report: Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Seagate Technology plc (NASDAQ:STX) - Beacon Chronicle
06/09/16 07:04 PMSarepta Therapeutics Inc: Piper Jaffray Upgrades Stock to Neutral - Bidness ETC
06/09/16 07:04 PMSarepta Therapeutics Inc. (SRPT) Jumps 7.97% on June 09 - Equities.com
06/09/16 05:27 PMWhy Envision Healthcare Holdings, Sarepta Therapeutics, and ABM Industries Jumped Today - Despite a slight market drop, these stocks gained ground. Find out why.
06/09/16 02:37 PMMid-Afternoon Market Update: Tailored Brands Tumbles On Downbeat Results; Sarepta Therapeutics Shares Spike Higher - Toward the end of trading Thursday, the Dow traded down 0.27 percent to 17,956.77 while the NASDAQ declined 0.47 percent to 4,951.13. The S&P also fell, dropping 0.34 percent to 2,112.01. Leading and Lagging Sectors Thursday afternoon, the utilities sector proved to be a source of strength for the market. Leading the sector was strength from Ameren Corp (NYSE: AEE) and Great Plains Energy Incorporated (NYSE: GXP). In trading on Thursday, basic materials shares fell by 1.9 percent. Meanwhile, top losers in the sector included Companhia Siderurgica Nacional (ADR) (NYSE: SID), down 9 percent, and Vale SA (ADR) (NYSE: VALE), down 9 percent. Top Headline J M Smucker Co (NYSE: SJM) reported stronger-than-expected earnings for its fourth quarter and offered upbeat forecast for the fiscal year 2017. J.M. Smucker Company reported net income of $191 million or $1.61 a share compared to a net loss of $90.3 million or a loss of $0.82 a share in the year-ago quarter. On an adjusted basis, it would have earned $1.86 a share, sharply up ...Full story available on Benzinga.com
06/09/16 11:54 AM9 Biggest Mid-Day Gainers For Thursday - Jaguar Animal Health Inc (NASDAQ: JAGX) shares jumped 95.45 percent to $2.58 as the company reported $15 million stock purchase agreement with Aspire Capital Fund, LLC. Staffing 360 Solutions Inc (NASDAQ: STAF) shares surged 32.82 percent to $2.59. Staffing 360 expects Q4 sales of $44 million and FY16 revenue of $165 million. Christopher & Banks Corporation (NYSE: CBK) shares climbed 14.36 percent to $2.31 as the company reported better-than-expected Q1 results. Sarepta Therapeutics Inc (NASDAQ: Full story available on Benzinga.com
06/09/16 09:39 AMAnalyst Review: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - News Oracle
06/09/16 09:39 AMSarepta Therapeutics Inc Headed Towards Accelerated Approval for Eteplirsen: Wedbush - Bidness ETC
06/09/16 09:39 AMHC Stocks To Observe: Sarepta Therapeutics Inc (NASDAQ:SRPT), Gilead Sciences, Inc. (NASDAQ:GILD) - share market updates (press release)
06/09/16 09:39 AMSarepta Therapeutics Inc. (SRPT) Jumps 22.55% on June 07 - Equities.com
06/09/16 08:57 AMSarepta Therapeutics: $5 Here We Come? -
06/08/16 07:05 PMCompany Update (NASDAQ:SRPT): Sarepta Therapeutics Inc Announces Proposed Offering - Smarter Analyst
06/08/16 04:51 PMAfter-Hours Social Sentiment In Sarepta Suggests Traders May Be Viewing Offering News As A Positive Indication - Sarepta Therapeutics Inc (NASDAQ: SRPT) shares have had an extremely volatile after-hours session following news of a $37.5 million offering. Immediately following the company press release, shares plunged to an after-hours low at $15.50. Shortly after, the stock had trimmed those losses and turned positive from the close, touching an extended-hour high around $20.47. About 50 minutes after the press release, Sarepta shares last traded at $19.25, down nearly a percent from Wednesday's close. The offering has caused confusion among investors and traders frequenting social networks like Twitter and StockTwits. Below are a ...Full story available on Benzinga.com
06/08/16 09:40 AMPerformance to see: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - News Oracle
06/08/16 09:40 AMAnalyst's Valuable Buzzers: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) , Zimmer Biomet Holdings, Inc. (NYSE:ZBH) - Street Updates
06/08/16 09:40 AMSAREPTA THERAPEUTICS INC. (NASDAQ:SRPT) Financial Condition Compared to S&P 500 - CML News
06/08/16 09:37 AMMid-Morning Market Update: Markets Open Higher; Lululemon Reports Mixed Q1 Results - Following the market opening Wednesday, the Dow traded up 0.41 percent to 18,011.24 while the NASDAQ climbed 0.28 percent to 4,975.64. The S&P also rose, gaining 0.33 percent to 2,119.07. Leading and Lagging Sectors Wednesday morning, the basic materials sector proved to be a source of strength for the market. Leading the sector was strength from AK Steel Holding Corporation (NYSE: AKS) and IAMGOLD Corp (USA) (NYSE: IAG). In trading on Wednesday, healthcare shares fell by 0.05 percent. Meanwhile, top losers in the sector included Enzo Biochem, Inc. (NYSE: ENZ), down 5 percent, and Sarepta Therapeutics Inc (NASDAQ: SRPT), down 5 percent. Top Headline Lululemon Athletica inc. (NASDAQ: LULU) reported weaker-than-expected adjusted earnings for the first quarter. However, revenue came in above the expected level. The company's earnings forecast for the second quarter also fell short of the expectations. Lululemon reported net income of $45.34 million in the first quarter, down from $47.81 million while earnings slipped to $0.33 a share from $0.34 a share in the year-ago quarter. Excluding adjustments, it would have earned only $0.31 a share thus missing the Street analysts' expectations by ...Full story available on Benzinga.com
06/08/16 01:04 AMSarepta Therapeutics (SRPT): Wedbush Upgrades Stock to Outperform - The firm presently has a $36.00 price target on the stock. They now have a Dollars 5 price target on the stock. It means it could lead to an approval, and shares In Sarepta rose over 40%. Shares of the company rose 24 percent to US$19.90 in extended ...
06/07/16 06:50 PMSarepta Therapeutics Inc (SRPT) Stock Skyrockets After FDA News - ValueWalk
About Sarepta Therapeutics

Sarepta Therapeutics logoSarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company's lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SRPT
  • CUSIP:
Key Metrics:
  • Previous Close: $18.66
  • 50 Day Moving Average: $18.44
  • 200 Day Moving Average: $19.84
  • P/E Ratio: N/A
  • P/E Growth: 20.40
  • Market Cap: $854.14M
  • Current Quarter EPS Consensus Estimate: $-4.54 EPS
Additional Links:
Sarepta Therapeutics (NASDAQ:SRPT) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha